The Atherosclerosis Market forecast predicts a steady, resilient expansion over the next decade, with market revenue expected to grow significantly, albeit often moderated by the impact of generic competition. The foundation of this optimistic forecast is the non-modifiable nature of key demographic drivers: the continued aging of the global population and the persistent high prevalence of underlying risk factors like obesity, hypertension, and Type 2 diabetes globally. As the elderly population grows, so does the incidence of clinical atherosclerotic events, generating a constant and increasing demand for both pharmacological and interventional treatments for conditions like coronary artery disease (CAD), stroke, and peripheral artery disease (PAD). This chronic and life-long nature of the disease ensures predictable, sustained market volume. Moreover, the forecast incorporates the increasing global efforts in preventive healthcare and early diagnosis. Enhanced public awareness and routine screening for dyslipidemia and high blood pressure are leading to earlier initiation of lipid-lowering therapies (statins and ezetimibe), expanding the patient base under long-term drug management, and stabilizing the foundational revenue streams of the market.

Crucially, the forecast models also heavily weigh the impact of pipeline innovation, particularly the introduction and market penetration of high-value, novel therapeutic classes aimed at the persistent residual risk. The commercial success of new agents like PCSK9 inhibitors (injectable biologics) and the recently approved anti-inflammatory drugs (e.g., low-dose Colchicine) is projected to generate substantial new revenue, targeting the high-risk patient segments who do not achieve optimal outcomes with statins alone. Furthermore, the forecast accounts for emerging, next-generation therapies, including RNA interference (RNAi) drugs like Inclisiran, which offer improved patient adherence through less frequent dosing (twice a year) and are expected to disrupt the standard of care for hypercholesterolemia. While the high cost of these biologics is factored in as a potential restraint in certain markets, their superior efficacy in high-risk groups guarantees their adoption in major developed economies, contributing disproportionately to the overall market valuation growth. Geographically, while North America and Europe will remain the high-value revenue drivers, the forecast anticipates the highest volume growth from the Asia-Pacific region, driven by its large, rapidly urbanizing population with increasingly Westernized lifestyles, which contribute to atherosclerotic risk.